Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fostamatinib Disodium

FDA-approved product (tablet, oral), marketed as Fostamatinib Disodium, Tavalisse.

Registered studies
27
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fostamatinib Disodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Autoimmune thrombocytopenic purpura
  • Hemorrhage
  • Thrombocytopenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other systemic hemostatics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

27registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fostamatinib Disodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fostamatinib Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults

    NCT06564207 · start 2026-08-30

    Registered record
    Registry ID
    NCT06564207
    Conditions
    Acute Respiratory Distress Syndrome; ARDS
    Interventions
    Placebo; Fostamatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-30
    Completion
    2027-10-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Distress Syndrome; ARDS
    InterventionPlacebo; Fostamatinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

    NCT04904276 · start 2021-05-18

    Registered record
    Registry ID
    NCT04904276
    Conditions
    ITP; Immune Thrombocytopenia
    Interventions
    Fostamatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-05-18
    Completion
    2022-11-17
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionITP; Immune Thrombocytopenia
    InterventionFostamatinib
    PhaseNot recorded
    Registry statusTerminated

  • Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

    NCT04629703 · start 2021-03-25

    Registered record
    Registry ID
    NCT04629703
    Conditions
    Covid19; SARS (Severe Acute Respiratory Syndrome); SARS Pneumonia; SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere; Pneumonia; Pneumonia, Viral
    Interventions
    Fostamatinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-03-25
    Completion
    2022-09-05
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS (Severe Acute Respiratory Syndrome); SARS Pneumonia; SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere +2 more
    InterventionFostamatinib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

    NCT04138927 · start 2019-10-30

    Registered record
    Registry ID
    NCT04138927
    Conditions
    Warm Antibody Autoimmune Hemolytic Anemia
    Interventions
    Fostamatinib disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2019-10-30
    Completion
    2024-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWarm Antibody Autoimmune Hemolytic Anemia
    InterventionFostamatinib disodium
    PhasePhase 3
    Registry statusEnrolling by invitation

  • A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

    NCT03764618 · start 2019-04-24

    Registered record
    Registry ID
    NCT03764618
    Conditions
    Warm Antibody Autoimmune Hemolytic Anemia
    Interventions
    Fostamatinib disodium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-04-24
    Completion
    2022-04-11
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWarm Antibody Autoimmune Hemolytic Anemia
    InterventionFostamatinib disodium; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

    NCT02612558 · start 2016-07

    Registered record
    Registry ID
    NCT02612558
    Conditions
    Warm Antibody Autoimmune Hemolytic Anemia
    Interventions
    Fostamatinib 150 mg bid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07
    Completion
    2019-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWarm Antibody Autoimmune Hemolytic Anemia
    InterventionFostamatinib 150 mg bid
    PhasePhase 2
    Registry statusCompleted

  • Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

    NCT02433236 · start 2015-09

    Registered record
    Registry ID
    NCT02433236
    Conditions
    IGA Nephropathy
    Interventions
    Fostamatinib Disodium tablet 100 mg; Fostamatinib Disodium tablet 150 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-09
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIGA Nephropathy
    InterventionFostamatinib Disodium tablet 100 mg; Fostamatinib Disodium tablet 150 mg
    PhasePhase 2
    Registry statusWithdrawn

  • A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

    NCT02076412 · start 2015-01

    Registered record
    Registry ID
    NCT02076412
    Conditions
    Immune Thrombocytopenic Purpura
    Interventions
    Fostamatinib Disodium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-08
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenic Purpura
    InterventionFostamatinib Disodium; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

    NCT02077192 · start 2014-10

    Registered record
    Registry ID
    NCT02077192
    Conditions
    Immune Thrombocytopenic Purpura
    Interventions
    Fostamatinib Disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2020-06-02
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenic Purpura
    InterventionFostamatinib Disodium
    PhasePhase 3
    Registry statusCompleted

  • A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

    NCT02076399 · start 2014-07-14

    Registered record
    Registry ID
    NCT02076399
    Conditions
    Immune Thrombocytopenic Purpura
    Interventions
    Fostamatinib disodium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-07-14
    Completion
    2016-04-21
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenic Purpura
    InterventionFostamatinib disodium; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

    NCT02092961 · start 2011-02

    Registered record
    Registry ID
    NCT02092961
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib; Adalimumab; Placebo of Fostamatinib; Placebo of Adalimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2013-07
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib; Adalimumab; Placebo of Fostamatinib; Placebo of Adalimumab
    PhasePhase 2
    Registry statusTerminated

  • Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

    NCT01242514 · start 2011-01

    Registered record
    Registry ID
    NCT01242514
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib; Fostamatinib; Fostamatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-01
    Completion
    2015-01
    Enrolment
    1,917

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib; Fostamatinib; Fostamatinib
    PhasePhase 3
    Registry statusTerminated

  • Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

    NCT01264770 · start 2011-01

    Registered record
    Registry ID
    NCT01264770
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib and placebo injections; Fostamatinib and placebo injections; Fostamatinib and placebo injections; Adalimumab and placebo of fostamatinib; Placebo of fostamatinib, fostamatinib, and placebo injections
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-01
    Completion
    2013-08
    Enrolment
    644

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib and placebo injections; Fostamatinib and placebo injections; Fostamatinib and placebo injections; Adalimumab and placebo of fostamatinib +1 more
    PhasePhase 2
    Registry statusTerminated

  • A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

    NCT01222455 · start 2010-10

    Registered record
    Registry ID
    NCT01222455
    Conditions
    Hepatic Impairment; Healthy Volunteers; Pharmacokinetics; Amount of R406 in Blood
    Interventions
    Fostamatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment; Healthy Volunteers; Pharmacokinetics; Amount of R406 in Blood
    InterventionFostamatinib
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

    NCT01197521 · start 2010-09

    Registered record
    Registry ID
    NCT01197521
    Conditions
    Rheumatoid Arthritis
    Interventions
    fostamatinib; fostamatinib; placebo, fostamatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-11
    Enrolment
    923

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventionfostamatinib; fostamatinib; placebo, fostamatinib
    PhasePhase 3
    Registry statusCompleted